Immune checkpoint blockade in experimental bacterial infections
Journal of Infection,
Год журнала:
2025,
Номер
unknown, С. 106391 - 106391
Опубликована: Янв. 1, 2025
Highlights•Immune
checkpoint
blockade
can
reduce
the
bacterial
burden
of
various
infections•The
efficacy
immune
in
infections
is
pathogen
dependent•Further
research
essential
for
clinical
translation
blockadeAbstractImmune
inhibitors
designed
to
reinvigorate
responses
suppressed
by
cancer
cells
have
revolutionized
therapy.
Similarities
dysregulation
between
and
infectious
diseases
has
prompted
investigations
into
role
checkpoints
diseases,
including
therapeutic
potential
drug
repurposing.
While
most
centered
around
viral
infections,
data
are
emerging.
This
systematic
review
reports
on
vivo
effect
selected
preclinical
studies
infection,
aiming
assess
if
there
could
be
a
rationale
using
immunotherapy
infections.
Of
42
analyzed
studies,
reduced
60%
had
no
28%
increased
12%.
Findings
suggest
that
context-dependent
part
relates
pathogen.
Further
required
understand
how
mediated
different
used
as
an
adjuvant
conventional
infection
management
strategies.
Язык: Английский
Emerging antimicrobial therapies for Gram-negative infections in human clinical use
npj Antimicrobials and Resistance,
Год журнала:
2025,
Номер
3(1)
Опубликована: Фев. 27, 2025
The
growing
problem
of
multi-drug
resistance
(MDR)
is
prevalent
in
Gram-negative
infections,
and
the
significant
decline
antibiotic
development
poses
a
critical
threat
to
global
public
health.
Many
emerging
non-antibiotic
therapies
have
been
proposed,
including
phage
therapy,
anti-virulence
agents,
antimicrobial
peptides,
plasmapheresis,
immunotherapy
options.
To
identify
most
likely
be
next
immediate
step
treatment
for
MDR
this
review
highlights
therapeutics
that
either
successfully
used
compassionate
care
or
are
currently
undergoing
clinical
trials.
Язык: Английский
Clinical characteristics and risk factors of late-stage lung adenocarcinoma patients with bacterial pulmonary infection and its relationship with cellular immune function
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 16, 2025
To
research
the
clinical
characteristics,
risk
factors,
correlation
between
bacterial
pulmonary
infection
and
immune
function
of
advanced
lung
adenocarcinoma
patients
complicated
with
infection.
334
stage
III
IV
admitted
to
first
affiliated
hospital
Zhengzhou
University
from
January
2020
March
2023
were
selected
divided
into
an
group
(n
=
240)
a
control
(n=
72)
according
whether
The
characteristics
analyzed.
microbiota
human
T
lymphocyte
subsets
(CD3+,
CD4+,
CD8+)
detected.
Multivariate
logistic
regression
analysis
was
performed
explore
factors
for
in
patients.
Among
patients,
264
cases
infection,
70
had
no
In
total,
544
pathogenic
bacteria
isolated
Of
these,
170
strains
(31.25%)
Gram-negative
bacilli,
162
(29.78%)
Gram-positive
cocci,
27
(4.96%)
bacilli.
There
statistically
significant
differences
age,
smoking,
combined
diseases,
TNM
staging,
CD3+
cell
percentage,
CD4+
percentage
two
groups
(P
<
0.05).
revealed
bronchiectasis,
diabetes
independent
leading
late-stage
those
on
checkpoint
inhibitors,
has
higher
number
cells
CD4+/CD8+
ratio
than
Smoking,
are
adenocarcinoma.
effect
inhibitor
treatment
is
more
pronounced
Gram
positive
bacteria.
Язык: Английский